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With Anti-CD20 alone With Anti-CD20 & Anti-KIR Therapy Anti-Ly49C/I F(ab') 2 enhances the anti-lymphoma activity of anti-CD20 mAb in vivo and is NK cell-dependent
• We present here pre-clinical evidence supporting another novel approach to enhancing mAb antitumor efficacy.
• Our findings provide rationale for the combination of an anti-KIR mAb to "remove the brakes" from NK cells and further enhance the efficacy of rituximab among other mAbs by augmentation of ADCC.
• A clinical trial investigating this strategy is needed.
Anti-Ly49C/I F(ab') 2 increases anti-CD20 mAb-mediated NK cell degranulation and cytotoxicity
• Purified NK cells from C57BL/6 mice were analyzed: (A) for degranulation by CD107a mobilization after 24 hour culture with five conditions: medium alone, human CD20-positive murine lymphoma cell line (EL4-huCD20) at a 1:1 ratio of NK cells: tumor cells, tumor and anti-CD20 mAb (CAT13, 10 µg/mL), tumor and anti-Ly49C/I F(ab') 2 (5E6, 10 µg/mL), or tumor, anti-CD20 mAb (10 µg/mL), and anti-Ly49C/I F(ab') 2 (10 µg/mL) (A, *p=.0109), (B) for IFN-γ production (ELISA) following a 4 hour culture in the conditions described above (B, *p=.001), and (C) in cytotoxicity assay with chromium labeled EL4-huCD20; percent lysis of target cells at varying E:T cell ratios cultured with medium alone (•), anti-Ly49C/I F(ab') 2 (10 µg/mL, ▲), anti-CD20 mAb (10 µg/mL,▼), or the combination of both (■) antibodies (C, *p=.019). • (A-B) Post-tumor inoculation, mice received either Rat IgG control (•), 250 µg of anti-CD20 mAb (CAT-13) on day 3 and weekly for three weeks (■), 200 µg of anti-Ly49C/I F(ab') 2 (5E6) on day 3 (▲) and biweekly for three weeks, or the combination (). Mice were then monitored for overall survival (B, *p=.042).
Conclusions
• (C-D) Post-tumor inoculation, mice received either Rat IgG control on day 3 (•), 50µL of anti-Asialo-GM1 on days -1, 0, 5, 10,15, 20, and 25 with 250 µg of anti-CD20 mAb and 200 µg anti-Ly49C/I F(ab') 2 on day 3 (■), 200µL liposomal (L.) clodronate on day -2 followed by 100µL on days 0, 4, 8, 12, 16, 20 , and 24 with 250 µg of anti-CD20 mAb and 200 µg of anti-Ly49C/I F(ab') 2 on day 3 (▼), 500 µg anti-CD8 mAb on days -1, 0, 5, 10,15, 20, and 25 with 250 µg of anti-CD20 mAb and 200 µg anti-Ly49C/I F(ab') 2 on day 3 (♦), or 250 µg of anti-CD20 mAb on day 3 and 200µg of anti-Ly49C/I F(ab') 2 on day 3 (▲) with 250µg of anti-CD20 mAb repeated weekly for three weeks and 200 µg of anti-Ly49C/I F(ab') 2 repeated biweekly for three weeks. Mice were then monitored for overall survival (D, *p<.001, n=10 mice per group).
• (E) shows survival with identical treatment groups (A-B), however with treatment delayed until day 10 post-tumor inoculation (E, *p=.005). • Rag1KO-Tg KIR mice (n=8 mice/group) received, starting five days after tumor challenge, either no treatment (o), isotype control at 0.5 mg/kg (), lirilumab at 0.5 mg/kg (•), or lirilumab at 0.5 mg/kg and 100 µg anti-NK1.1 mAb (■) to deplete NK cells starting on day prior to tumor inoculation. Mice were then monitored for overall survival (*p=.0002).
• (A-B) Starting five days after tumor challenge, Rag1KO-Tg KIR mice (n=8 mice/group) received either isotype controls (), lirilumab i.v. at 0.5 mg/kg on day 5 (•), or rituximab i.p. at 0.12 mg/kg on days 5, 8 and 12 (▼) Mice were then monitored for overall survival.
• (C) To determine the role of NK cells, Rag1KO-Tg KIR mice (n=8 mice/group) received either isotype controls (), lirilumab at 0.5 mg/kg on day 5 and rituximab at 0.12 mg/kg on days 5, 8 and 12 (♦), or lirilumab at 0.5 mg/kg on day 5 and rituximab at 0.12 mg/kg on days 5, 8 and 12 and 100 µg of anti-NK1.1 mAb on day 4 (■) to deplete NK cells Mice were then monitored for overall survival (C, *p<.001).
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